Previous 10 | Next 10 |
2023-05-09 06:34:00 ET 3 Tips for Momentum Trading Penny Stocks in 2023 Momentum trading has long been an attractive strategy for investors seeking to capitalize on short-term market trends and fluctuations. In the world of penny stocks , this approach presents a unique opportunity ...
Trevena, Inc. (NASDAQ: TRVN) is one of today's top gainers. The company's shares are currently up 372.94% on the day to $3.05. Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorde...
2023-05-08 10:34:40 ET This will surely be another wild week for investors. Regional bank stocks are surging to start the Monday session as cooler heads prevail after last week’s insanity. But then you’ve got upcoming catalysts like Wednesday’s May CPI inflation data, m...
2023-05-08 08:53:52 ET Trevena ( NASDAQ: TRVN ) said its partner Jiangsu Nhwa received approval from China's National Medical Products Administration (NMPA) for opioid pain drug Olinvyk. The NMPA approved Olinvyk (oliceridine) for use in adults for managing...
Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on first commercial sale in China, based on ex-US...
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participa...
2023-03-31 15:07:10 ET Trevena, Inc. (TRVN) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark...
2023-03-30 07:44:17 ET Trevena ( NASDAQ: TRVN ) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine). VOLITION : The study, dubbed VOLITION, enrolled 203 patients. Olinvyk-treated patients had a 52.2% gastroin...
2023-03-30 07:02:00 ET Trevena press release ( NASDAQ: TRVN ): Q4 GAAP EPS of -$0.73 beats by $1.01 . Cash and cash equivalents were $38.3M as of December 31, 2022, which the company believes will be sufficient to fund its operating expenses and capital expenditure req...
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMIS patients at Wake Forest Baptist Health OLINVYK-treated patients...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...